Register now

To access the site, please provide the required information to verify that you are a Canadian healthcare professional and create an account. Once validated, this account can be used to log in to all myAstraZeneca websites for Canadian healthcare professionals. Please use the first and last name registered with your professional college.

Login/Register
EN FR

CASPIAN Trial OS Data

Understanding IMFINZI treatment for your patients with extensive-stage small cell lung cancer (ES-SCLC)

IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC).1

Start with IMFINZI + EP in the first-line setting in your patients with ES-SCLC.

Be IN the know with IMFINZI’s CASPIAN OS data

CASPIAN: Primary OS analysis (full analysis set, median duration of follow-up 14.2 [11.7‒17.0] months [censored patients])1,2

27% relative reduction in instantaneous risk of death for IMFINZI + EP vs. EP alone1

HR: 0.73 (95% CI: 0.591, 0.909); p=0.00471

mOS: IMFINZI + EP vs. EP alone

13.0 months (95% CI: 11.5, 14.8) for IMFINZI + EP vs. 10.3 months (95% CI: 9.3, 11.2) for EP alone1

See study parameters below.†
CI, confidence interval; EP, etoposide and either carboplatin or cisplatin; HR, hazard ratio; mOS, median overall survival; OS, overall survival.

CASPIAN: 3-year updated OS analysis
(planned exploratory analysis, median duration of follow-up 39.4 [0.1‒47.5] months)3*

Planned exploratory analysis from the CASPIAN trial showed sustained OS benefit at 3 years consistent with the primary analysis.1-3†

Click here to view the full study and learn more. This link redirects you to a website intended for the general public.

View the full study

Back to top

† CASPIAN was an open-label, phase III study in which patients with treatment-naïve ES-SCLC and World Health Organization performance status 0/1 were randomized 1:1 to IMFINZI 1,500 mg + etoposide (80‒100 mg/m2) on Days 1, 2, and 3 and either carboplatin (AUC 5 or 6 mg/mL/min) or cisplatin (75‒80 mg/m2) on Day 1 (EP), or EP. Patients in the immunotherapy arm received 4 cycles of EP + IMFINZI 1,500 mg Q3W, followed by maintenance IMFINZI 1,500 mg Q4W until disease progression or unacceptable toxicity. Patients in the EP arm received up to 6 cycles of EP and optional prophylactic cranial irradiation. Administration of IMFINZI monotherapy was permitted beyond disease progression if the patient was clinically stable and deriving clinical benefit as determined by the investigator (not recommended). In this planned exploratory analysis (data cut-off 22 March 2021), long-term follow-up for the primary endpoint of OS (time from randomization until death from any cause) for IMFINZI + EP vs. EP are reported.3

EP, etoposide and either carboplatin or cisplatin; ES-SCLC, extensive-stage small cell lung cancer; OS, overall survival; Q3W, every 3 weeks; Q4W, every 4 weeks.

References:

  1. IMFINZI Product Monograph. AstraZeneca Canada Inc. February 20, 2026.
  2. Paz-Ares L, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929-1939.
  3. Paz-Ares L, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2):100408.

Back to top